The use of platelet-rich plasma in studies with early knee osteoarthritis versus advanced stages of the disease: a systematic review and meta-analysis of 31 randomized clinical trials

Vílchez-Cavazos, Félix; Blázquez-Saldaña, Jaime; Gamboa-Alonso, Augusto; Peña‐Martínez, Víctor M.; Acosta-Olivo, Carlos; Sánchez‐García, Adriana; Simental‐Mendía, Mario

doi:10.1007/s00402-021-04304-1

Cited by 14 publications

(5 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, there are other treatments that suppress inflammation and pain by injecting hyaluronic acid and steroids into the joint cavity, but there is the possibility that pain will worsen, or bacterial infection will occur after administration [8,9]. Recently, platelet-rich plasma therapy, which concentrates plasma isolated from the patient's own blood and injects it into the treatment site, has been spotlighted, and the treatment rate is currently being discussed positively in many review papers [10][11][12]. Therapeutics are evolving innovatively, but there is still no complete cure.…”

Section: Introductionmentioning

confidence: 99%

Chondroprotective Effects of 4,5-Dicaffeoylquinic Acid in Osteoarthritis through NF-κB Signaling Inhibition

et al. 2022

View full text Add to dashboard Cite

Osteoarthritis (OA) is characterized by cartilage degradation, inflammation, and pain. The dicaffeoylquinic acid (diCQA) isomer, 4,5-diCQA, exhibits antioxidant activity and various other health-promoting benefits, but its chondroprotective effects have yet to be elucidated. In this study, we aimed to investigate the chondroprotective effects of 4,5-diCQA on OA both in vitro and in vivo. Primary rat chondrocytes were pre-treated with 4,5-diCQA for 1 h before stimulation with interleukin (IL)-1β (5 ng/mL). The accumulation of nitrite, PGE2, and aggrecan was observed using the Griess reagent and ELISA. The protein levels of iNOS, COX-2, MMP-3, MMP-13, ADMATS-4, MAPKs, and the NF-κB p65 subunit were measured by Western blotting. In vivo, the effects of 4,5-diCQA were evaluated for 2 weeks in a destabilization of the medial meniscus (DMM)-surgery-induced OA rat model. 4,5-diCQA significantly inhibited IL-1β-induced expression of nitrite, iNOS, PGE2, COX-2, MMP-3, MMP-13, and ADAMTS-4. 4,5-diCQA also decreased the IL-1β-induced degradation of aggrecan. It also suppressed the IL-1β-induced phosphorylation of MAPKs and translocation of the NF-κB p65 subunit to the nucleus. These findings indicate that 4,5-diCQA inhibits DMM-surgery-induced cartilage destruction and proteoglycan loss in vivo. 4,5-diCQA may be a potential therapeutic agent for the alleviation of OA progression. In this study, diclofenac was set to be administered once every two days, but it showed an effect on OA. These results may be used as basic data to suggest a new dosing method for diclofenac.

show abstract

Section: Introductionmentioning

confidence: 99%

Chondroprotective Effects of 4,5-Dicaffeoylquinic Acid in Osteoarthritis through NF-κB Signaling Inhibition

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Finally, a total of 28 meta-analyses involving 32 763 participants were eligible for this quantitative umbrella meta-analysis. 1 , 4 , 12 , 20 , 25 – 48 There were 10 studies for MSCs (4876 patients), 4 , 25 , 29 , 34 – 36 , 39 , 41 , 42 , 46 16 studies for PRP (26 914 patients), 1 , 26 – 28 , 30 – 33 , 37 , 38 , 40 , 43 – 45 , 47 , 48 and 2 combination studies (973 patients). 12 , 20 For studies on the effect of MSCs on KOA outcomes, there were 9 studies (20 effect sizes) on VAS, 4 , 25 , 29 , 34 – 36 , 39 , 42 , 46 10 studies (21 effect sizes) on the WOMAC total score, 4 , 25 , 29 , 34 – 36 , 39 , 41 , 42 , 46 3 studies (6 effect sizes) on WOMAC pain score, 4 , 35 , 39 4 studies (7 effect sizes) on the WOMAC function score, 4 , 29 , 39 , 41 4 studies (7 effect sizes) on the WOMAC stiffness score, 4 , 29 , 39 , 41 5 studies (6 effect sizes) on the Lysholm score, 29 ,…”

Section: Resultsmentioning

confidence: 99%

“… 12 , 20 For studies on the effect of MSCs on KOA outcomes, there were 9 studies (20 effect sizes) on VAS, 4 , 25 , 29 , 34 – 36 , 39 , 42 , 46 10 studies (21 effect sizes) on the WOMAC total score, 4 , 25 , 29 , 34 – 36 , 39 , 41 , 42 , 46 3 studies (6 effect sizes) on WOMAC pain score, 4 , 35 , 39 4 studies (7 effect sizes) on the WOMAC function score, 4 , 29 , 39 , 41 4 studies (7 effect sizes) on the WOMAC stiffness score, 4 , 29 , 39 , 41 5 studies (6 effect sizes) on the Lysholm score, 29 , 34 , 35 , 39 , 46 5 studies (7 effect sizes) on the WORMS, 4 , 29 , 34 – 36 2 studies (3 effect sizes) on the IKDC score, 36 , 39 and 4 studies (5 effect sizes) on the KOOS. 34 , 36 , 42 , 46 For studies on the effect of PRP on KOA outcomes, there were 15 studies (30 effect sizes) on VAS, 1 , 26 – 28 , 30 – 33 , 37 , 40 , 43 – 45 , 47 , 48 13 studies (27 effect sizes) on the WOMAC total score, 26 – …”

Section: Resultsmentioning

confidence: 99%

Mesenchymal stem cells and platelet rich plasma therapy for knee osteoarthritis: an umbrella review of systematic reviews with meta-analysis

Lin,

Zhang,

Cui

2024

Ann Saudi Med

View full text Add to dashboard Cite

The effect of mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) therapy on knee osteoarthritis (KOA) has been contradictory in previous meta-analyses. This umbrella review on published meta-analyses aimed to investigate the effect of MSCs and PRP on KOA. We systematically searched Scopus, PubMed, and Cochrane databases to include related meta-analyses. The outcome included studies reporting visual analog scale scores, the Western Ontario and McMaster Universities Osteoarthritis Index, Whole-Organ Magnetic Resonance Imaging Scores, International Knee Documentation Committee scores, and the Knee injury and Osteoarthritis Outcome Score. A total of 28 meta-analyses with 32 763 participants. MSCs and PRP therapies were significantly associated with an improvement in KOA scores. This umbrella meta-analysis supports the beneficial health effects of MSCs and PRP in KOA.

show abstract

“…Our choice to use high volume and very pure PRP could partly account for the satisfactory outcomes in severe patients. Moreover, a recent meta-analysis indicated that the degree of cartilage damage did not impact on PRP efficacy [ 52 ]. We also observed that patients presenting a PF KOA are more likely to have lower functional improvement at 12 months.…”

Section: Discussionmentioning

confidence: 99%

Long term improvement of knee osteoarthritis after injection of single high/very high volume of very pure PRP: A retrospective analysis of patients optimally managed in dedicated centers

Prost,

Bardot,

Baud

et al. 2024

Regenerative Therapy

View full text Add to dashboard Cite

The use of platelet-rich plasma in studies with early knee osteoarthritis versus advanced stages of the disease: a systematic review and meta-analysis of 31 randomized clinical trials

Cited by 14 publications

References 61 publications

Chondroprotective Effects of 4,5-Dicaffeoylquinic Acid in Osteoarthritis through NF-κB Signaling Inhibition

Chondroprotective Effects of 4,5-Dicaffeoylquinic Acid in Osteoarthritis through NF-κB Signaling Inhibition

Mesenchymal stem cells and platelet rich plasma therapy for knee osteoarthritis: an umbrella review of systematic reviews with meta-analysis

Long term improvement of knee osteoarthritis after injection of single high/very high volume of very pure PRP: A retrospective analysis of patients optimally managed in dedicated centers

Contact Info

Product

Resources

About